Evgen Pharma Plc, which is developing cancer and neurology products based on a naturally occurring chemical, has announced its intention to make an initial public offering of up to £20 million worth of its shares on the AIM market of the London Stock Exchange in mid-December.
BTG Plc is to pay up to $475 million to acquire privately-held PneumRx Inc of California which has a medical device approved in Europe to treat emphysema. The purchase price consists of an upfront payment of $230 million and up to $245 million in milestones.
France-based TxCell SA has enrolled the first patient in a new trial of its cell therapy for Crohn’s disease which aims to demonstrate that 160 patients with refractory disease can experience relief. Crohn’s is an inflammatory bowel disease affecting the gastrointestinal tract.
Israel-based Pluristem Therapeutics Inc has entered into a long-term collaboration with the Hadassah Medical Center in Jerusalem to assess the potential efficacy of a cell therapy for the treatment of complications arising from bone marrow transplantations.
Sanofi SA and Evotec AG are in negotiations for a collaboration under which Evotec would assume much of Sanofi’s drug discovery operations, including the management of the French company's global screening compound library in Toulouse.
Switzerland-based GeNeuro SA and Les Laboratoires Servier SAS of France have formed a partnership to develop an antibody that targets a protein expressed in the brain lesions of patients with multiple sclerosis thereby addressing a causal factor of the disease.
Ascendis Pharma A/S, a Denmark-based specialty pharmaceutical company with new prodrug technology, has raised $60 million from a syndicate co-led by US-based Sofinnova Ventures.
BioMarin Pharmaceutical Inc of California has made an agreed bid to buy Prosensa Holding NV of the Netherlands for $680 million in cash.
London-based Cell Medica Ltd has raised £50 million from institutional investors to support development of its lead oncology product, CMD-003, for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus.
Promethera Biosciences SA, a Belgian company developing cell-based treatments for in-born errors of metabolism and acquired liver disease, has raised €20.3 million in a Series C venture capital round and €5 million in loans and subsidies from the regional government of Wallonia.